Exelixis, Inc. (NASDAQ:EXEL) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET
Company Participants
Susan Hubbard - EVP, Public Affairs & IR
Michael Morrissey - CEO, President & Director
Christopher Senner - EVP & CFO
Patrick Haley - EVP, Commercial
Vicki Goodman - EVP, Product Development & Medical Affairs and Chief Medical Officer
Peter Lamb - EVP, Scientific Strategy & Chief Scientific Officer
Conference Call Participants
Jason Gerberry - Bank of America Merrill Lynch
Michael Schmidt - Guggenheim Securities
Andy Hsieh - William Blair & Company
Peter Lawson - Barclays Bank
Jay Olson - Oppenheimer
Etzer Darout - BMO Capital Markets
Yaron Werber - Cowen and Company
Operator
Good day, ladies and gentlemen, and welcome to the Exelixis Second Quarter 2022 Financial Results Conference Call. My name is Sarah, and I'll be your operator for today. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. Please proceed.
Susan Hubbard
Thank you, Sarah, and thank you all for joining us for the Exelixis Second Quarter 2022 Financial Results Conference Call.
Joining me on today's call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; P.J. Haley, our Executive Vice President of Commercial; Vicki Goodman, our Chief Medical Officer; and Peter Lamb, our Chief Scientific Officer, who will together review our progress for the second quarter 2022 ended June 30, 2022.
During the call today, we will refer to financial measures not calculated according to generally accepting accounting principles. Please refer to today's press release, which is posted on our website for an explanation of our reasons for using such non-GAAP measures as well as tables deriving these measures from our GAAP results.
During the course of this presentation, we will be making forward-looking statements regarding future events and the future performance of the company. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial and strategic matters. Actual events or results could, of course, differ materially. We refer you to the documents we file from time to time with the SEC, which under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed by the company verbally and in writing today, including, without limitation, risks and uncertainties related to product commercial success, market competition, regulatory review and approval processes, conducting clinical trials, compliance with applicable regulatory requirements, our dependence on collaboration partners and the level of cost associated with discovery, product development, business development and commercialization activities.